Integrating efficacy and safety profile in advanced HCC: A network meta-analysis of first-line systemic therapies
JNCI Cancer Spectrum · 21.08.2026
DOI: 10.1093/jncics/pkag084 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 21.08.2026. Verfasst von Wei Yu Chua und 9 weiteren Autor:innen. Beteiligte Einrichtung: Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Hepatocellular carcinoma(HCC) is the sixth most common cancer and the third leading cause of cancer-related death worldwide. Our updated network meta-analysis aims to compare and rank first-line treatment regimens for advanced HCC.
Methods
We searched PubMed, EMBASE, Scopus, and Cochrane from inception to May 2025 for phase III RCTs investigating first-line systemic therapies for advanced HCC. Derived hazard ratios(HRs) for each study were pooled in a random-effects NMA. The primary outcome was overall survival(OS), progression-free survival(PFS), objective response rate(ORR), and ≥ Grade 3 treatment-related adverse events(TRAE) of the assessed treatment in comparison to Sorafenib and Lenvatinib. Subgroup analysis for OS and PFS was conducted using study-level HRs. P-scores were used to rank the treatment strategies numerically.
Results
Seventeen studies involving 12,727 patients were included in the final analysis. Nivolumab-Ipilimumab(HR:0.61,95%CI:0.44–0.84), Atezolizumab-Bevacizumab(HR:0.66,95%CI:0.48–0.90), Durvalumab-Tremelimuma(HR:0.76,95%CI:0.59-0.97), Sintilimab-BevSim(HR:0.57,95%CI:0.41-0.80), and Camrelizumab-Rivoceranib(HR:0.62,95%CI:0.45-0.85) had superior OS compared to Sorafenib. Only Sintilimab-BevSim(HR:0.66,95%CI:0.44-0.99) and Nivolumab-Ipilimumab(HR:0.70,95%CI:0.54-0.92) had superior OS compared to Lenvatinib. Based on p-score rankings only, Nivolumab-Ipilimumab had the highest p-score for OS, PFS, and ORR among the three FDA and EMA approved combination regimens, with similar ≥ Grade 3 TRAE compared to Sorafenib. In the subgroup analysis, Atezolizumab-Cabozantinib has the highest p-score for HBV, Atezolizumab-Bevacizumab the highest for HCV, Durvalumab-Tremelimumab for non-viral aetiology, and Pembrolizumab-Lenvatinib for AFP≥400.
Conclusion
Our NMA comprehensively compares therapeutic regimens across key clinical outcomes, including OS, PFS, ORR, and ≥ Grade 3 TRAE. The heterogeneity in treatment responses across patient subgroups underscores the importance of personalized approaches in managing HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Department of Medicine, National University Hospital, Singapore, Singapore.
- Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
- Song-dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea.
- National Institute of Cancer Research, National Health Research Institutes, Taiwan.
Zitieren
APA
Chua, W. Y., Zhao, J. J., Lee, C. K., Su, Y. Y., Lee, S. Y., Lee, J. J. X., Tai, D. W., Tan, S. H., Sundar, R., & Ng, K. Y. Y. (2026). Integrating efficacy and safety profile in advanced HCC: A network meta-analysis of first-line systemic therapies. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkag084
Vancouver
Chua WY, Zhao JJ, Lee CK, Su YY, Lee SY, Lee JJX, et al. Integrating efficacy and safety profile in advanced HCC: A network meta-analysis of first-line systemic therapies. JNCI Cancer Spectrum. 2026. doi:10.1093/jncics/pkag084
BibTeX
@article{Chua2026,
author = {Chua, Wei Yu and Zhao, Joseph J and Lee, Choong-Kun and Su, Yung-Yeh and Lee, Suat Ying and Lee, Joycelyn Jie Xin and Tai, David Wai-Meng and Tan, Sze Huey and Sundar, Raghav and Ng, Kennedy Yao Yi},
title = {Integrating efficacy and safety profile in advanced HCC: A network meta-analysis of first-line systemic therapies},
journal = {JNCI Cancer Spectrum},
year = {2026},
doi = {10.1093/jncics/pkag084}
}
EUVIMED